Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia.
about
Drugs under preclinical and clinical study for treatment of acute and chronic lymphoblastic leukemiaOvercoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibitionAn evidence-based review of obatoclax mesylate in the treatment of hematological malignanciesThe Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
P2860
Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Obatoclax in combination with ...... chronic lymphocytic leukemia.
@en
type
label
Obatoclax in combination with ...... chronic lymphocytic leukemia.
@en
prefLabel
Obatoclax in combination with ...... chronic lymphocytic leukemia.
@en
P2093
P2860
P1433
P1476
Obatoclax in combination with ...... chronic lymphocytic leukemia.
@en
P2093
A S Freedman
Bethany Tesar
Christina Thompson
David C Fisher
Donna Neuberg
Evgeny Mikler
Hazel M Reynolds
Jennifer R Brown
Lillian Werner
P2860
P304
P356
10.3109/10428194.2015.1048441
P577
2015-05-13T00:00:00Z